Minerva Neurosciences, Inc.

NERV
$4.39 (- $0.12 - 2.66%)
Last updated: 2026-06-16 10:25 UTC
NERV Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS6033801068
CUSIP603380106
Market Price4.39
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-1.85
Market Cap$27.8M
Book Value-4.95
Price to Book-0.803
Beta-0.41
52w High12.46
52w Low1.15
Next Earnings DateN/A

Minerva Neurosciences, Inc. trades under ticker NERV on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US6033801068, CUSIP 603380106.

About the Company
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Price History